Literature DB >> 33649873

The Role of Radiation Therapy for Symptomatic Desmoid Tumors.

Wen Shen Looi1, Daniel J Indelicato2, Michael S Rutenberg1.   

Abstract

OPINION STATEMENT: Desmoid tumors have a variable clinical course that ranges from indolence or spontaneous regression to an aggressive pattern marked by local invasion. Up to half may remain stable or regress; watchful waiting is the preferred approach in the initial management of desmoid tumors. Symptomatic or progressive tumors or those that may affect adjacent critical structures require surgery, radiotherapy, or systemic therapy. Although radiotherapy effectively controls desmoid tumors in most cases, concerns regarding late toxicity exist. Definitive radiotherapy for macroscopic disease is indicated when a non-morbid complete surgical resection cannot be accomplished and provides similar control rates to surgery plus radiotherapy but avoids toxicity from combined-modality treatment (surgery and radiotherapy). Adjuvant radiotherapy can be considered for microscopically involved margins, particularly for recurrent cases or when a future recurrence may be challenging to treat. Large size, extremity site, and younger age are poor prognostic factors after radiotherapy. In the extremity, radiotherapy may have superior outcomes to surgery. Younger patients, especially children, are challenging to manage as they are at particular risk for late toxicity due to the number of potential years at risk. For patients under 20 years old, for whom a non-morbid complete resection is not possible, we recommend systemic therapy as the first line of treatment. Although the long-term efficacy of systemic therapy is unproven, this strategy allows additional time for growth and development prior to radiotherapy. In younger patients and those with axial desmoid tumors adjacent to critical organs, consideration should be given to using proton therapy as the dosimetric advantages may mitigate some of the toxicity associated with conventional radiotherapy.

Entities:  

Keywords:  Aggressive fibromatosis; Benign; Radiation therapy; Soft tissue; Treatment outcomes; Treatment toxicity

Mesh:

Year:  2021        PMID: 33649873     DOI: 10.1007/s11864-021-00831-6

Source DB:  PubMed          Journal:  Curr Treat Options Oncol        ISSN: 1534-6277


  91 in total

1.  Radiation therapy for aggressive fibromatosis (desmoid tumors): results of a national Patterns of Care Study.

Authors:  Oliver Micke; M Heinrich Seegenschmiedt
Journal:  Int J Radiat Oncol Biol Phys       Date:  2005-03-01       Impact factor: 7.038

2.  Desmoid tumors -- a characterization of patients seen at Mayo Clinic 1976-1999.

Authors:  Taya Fallen; Marcia Wilson; Bruce Morlan; Noralane M Lindor
Journal:  Fam Cancer       Date:  2006       Impact factor: 2.375

3.  A nation-wide study comparing sporadic and familial adenomatous polyposis-related desmoid-type fibromatoses.

Authors:  Marry H Nieuwenhuis; Mariel Casparie; Lisbeth M H Mathus-Vliegen; Olaf M Dekkers; Pancras C W Hogendoorn; Hans F A Vasen
Journal:  Int J Cancer       Date:  2010-11-03       Impact factor: 7.396

4.  Comparison of sporadic and FAP-associated desmoid-type fibromatoses.

Authors:  Laura Koskenvuo; Ari Ristimäki; Anna Lepistö
Journal:  J Surg Oncol       Date:  2017-06-01       Impact factor: 3.454

Review 5.  Desmoid tumors: clinical features and treatment options for advanced disease.

Authors:  Bernd Kasper; Philipp Ströbel; Peter Hohenberger
Journal:  Oncologist       Date:  2011-04-08

6.  The desmoid tumor. II. Analysis of factors possibly contributing to the etiology and growth behavior.

Authors:  P Häyry; J J Reitamo; S Tötterman; D Hopfner-Hallikainen; A Sivula
Journal:  Am J Clin Pathol       Date:  1982-06       Impact factor: 2.493

7.  The desmoid tumor. I. Incidence, sex-, age- and anatomical distribution in the Finnish population.

Authors:  J J Reitamo; P Häyry; E Nykyri; E Saxén
Journal:  Am J Clin Pathol       Date:  1982-06       Impact factor: 2.493

8.  Desmoid-type fibromatosis and pregnancy: a multi-institutional analysis of recurrence and obstetric risk.

Authors:  Marco Fiore; Sara Coppola; Amanda J Cannell; Chiara Colombo; Monica M Bertagnolli; Suzanne George; Axel Le Cesne; Rebecca A Gladdy; Paolo G Casali; Carol J Swallow; Alessandro Gronchi; Sylvie Bonvalot; Chandrajit P Raut
Journal:  Ann Surg       Date:  2014-05       Impact factor: 12.969

9.  Thirty years of experience with desmoid tumors at Charity Hospital.

Authors:  G F Gansar; I P Markowitz; E J Cerise
Journal:  Am Surg       Date:  1987-06       Impact factor: 0.688

10.  Time trends in the incidence and treatment of extra-abdominal and abdominal aggressive fibromatosis: a population-based study.

Authors:  Danique L M van Broekhoven; Dirk J Grünhagen; Michael A den Bakker; Thijs van Dalen; Cornelis Verhoef
Journal:  Ann Surg Oncol       Date:  2015-06-05       Impact factor: 5.344

View more
  1 in total

1.  Cryotherapy in extra-abdominal desmoid tumors: A systematic review and meta-analysis.

Authors:  Bimal Mayur Kumar Vora; Peter L Munk; Nagavalli Somasundaram; Hugue A Ouellette; Paul I Mallinson; Adnan Sheikh; Hanis Abdul Kadir; Tien Jin Tan; Yet Yen Yan
Journal:  PLoS One       Date:  2021-12-23       Impact factor: 3.240

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.